| |NOVEMBER 20258GSK PARTNERS WITH SYNDIVIA ON INNOVATIVE ADC FOR PROSTATE CANCERINDIA PROBES DUMPING OF TB DRUG IMPORTS FROM CHINA, THAILANDIndia released a list of registered interested parties on Monday, advancing an anti-dumping inquiry into imports of ethambutol hydrochloride, an active pharmaceutical ingredient used in anti-tuberculosis medications, from China and Thailand.Following a plea by domestic pharmaceutical company Lupin Ltd. alleging that imports were being dumped at unreasonably cheap prices, harming Indian producers, the Directorate General of Trade Remedies (DGTR) opened the probe last month.The inquiry coincides with India's increased attempts to combat unfair trade practices that hurt homegrown businesses. In September, the trade remedies authority released 15 final conclusions on such practices in a variety of industries, from steel and glass fiber to chemical products and solar cells.On Monday, the DGTR indicated Lupin Ltd as the participant from the domestic industry and Wuhan Wuyao Pharmaceuticals Co. Ltd of China amongst the foreign respondents.The DGTR stated that they had found evidence of both dumping and injury, with products imported at prices lower than domestic prices.The investigation will cover the period from April 2024 to March 2025 and if it is determined that there was injury to the Indian industry then anti-dumping duties may be applied.In September, the DGTR commenced 13 additional anti-dumping and countervailing investigations, primarily covering imports from China and South Korea. POTOP STORIESGSK has signed a global exclusive deal with Syndivia - a privately-held biotech dedicated to developing next-generation antibody-drug conjugates (ADCs) - for the advancement and commercialization of a preclinical ADC for patients with metastatic castration-resistant prostate cancer (mCRPC).This ADC utilizes Syndivia's GeminiMab conjugation technology to achieve improved efficacy against tumours while maintaining a robust safety profile.In preclinical studies of this experimental therapy, a statistically significant reduction in tumour growth was observed without any associated increases in side effects, including at the maximum doses. GSK believes this could ultimately provide a best-in-class treatment option for prostate cancer patients, where potential options, especially in community practice, are limited at this time.Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: "Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings."Sasha Koniev, Chief Executive Officer, Syndivia, said: "We are proud that GSK will advance this programme on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs."The deal strengthens GSK's expanding oncology pipeline, which includes ADCs with diverse antigens and payloads, next-generation small molecules, and T-cell engagers. Together with GSK's B7-H3-targeting ADC, GSK'227, the new candidate reinforces the company's push to develop innovative treatments across multiple stages of prostate cancer.Under the terms, Syndivia will receive an upfront payment and milestone payments of up to £268 million, along with tiered royalties on global sales. GSK will take full charge of development, manufacturing, and worldwide commercialization of the ADC, marking a major step forward in next-generation ADC innovation for prostate cancer. PO
< Page 7 | Page 9 >